Survival rates for many cancers have improved significantly over the past several decades due to progress in early detection, the advent of precision medicine, and advances in treatments. 1 By contrast, brain tumors continue to be an exception to this trend with long-term survivorship remaining unacceptably low. Glioblastoma (GBM) is the most common primary brain tumor in adults and is almost uniformly lethal with less than 10% of patients living beyond 5 years, and a median survival of 16-20 months. 2,3 In children and young adults, primary brain tumors continue to be the leading cause of cancer-related deaths. 4
The refractory nature of brain tumors to standard therapies provides compelling motivation for developing novel treatment interventions.
The tremendous progress in T cell immunotherapy across a broad range of tumor types provides hope that the immune system can be augmented to improve outcomes for patients with brain tumors. The brain, however, is an immune-specialized organ presenting unique and specific challenges to the application of immunotherapy. Immune system access to the brain is tightly controlled and the immunosuppressive nature of the central nervous system (CNS) has evolved to protect against immunologic attack. 8 Toxicity risks are also significant and potentially life-threatening, including off-tumor targeting of normal brain tissue and CNS inflammatory reactions. 9 Although these challenges are considerable, emerging data supports the promise of the T cell immunotherapy for brain tumors.
Approaches to stimulate or enhance endogenous T cell immune responses to treat brain tumors are showing evidence of bioactivity, including clinical studies of tumor neoantigen vaccines, 10 oncolytic viruses, 11 and immune checkpoint inhibitors (ICIs). 12, 13 The engagement of checkpoint receptors such as programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) dampen anti-tumor immune responses, and these checkpoint pathways have emerged as critical drivers of immunosuppression in solid cancers. 14 In melanoma patients with CNS metastases, a phase II study evaluating nivolumab (anti-PD-1) combined with ipilimumab (anti-CTLA-4), reported that ICIs mediate intracranial clinical benefit in 57% of the patients with a 26% complete response rate. 15 Remarkably, ICI clinical response rates against melanoma CNS metastases were durable and on par with systemic anti-tumor responses.
High tumor mutational burden (TMB; >20 mutations/mb) has previously been identified as an independent prognostic variable to response with ICI, 16 and melanoma has some of the highest TMB of all malignancies, possibly contributing to the encouraging clinical results. Similar observations have also been reported in a subset of GBMs with high mutational burden due to mismatch repair deficiencies, and in these cases ICIs have also been shown to achieve complete and durable responses. 17, 18 Most brain tumors, however, including GBM and pediatric brain tumors, have low TMB and have been less responsive to ICIs. 19 Encouragingly, neoadjuvant ICI prior to surgical resection has been shown to mediate a survival benefit in recurrent GBM, possibly by augmenting endogenous T cell responses. 20 These studies are important as they establish that brain tumors are not impervious to immunological recognition and attack, and point to immunotherapy making inroads in brain tumor treatment.
For most patients, endogenous immune responses are not potent or abundant enough to mount sufficient anti-tumor responses even with ICI treatment, and thus the engineering of new T cell immunity using chimeric antigen receptors (CARs) is a rapidly advancing approach for the treatment of cancer. 21 CAR T cells can be efficiently expanded ex vivo and delivered in large quantities to elicit tumor destruction. Tumor targeting by CARs is independent of major histocompatibility complex (MHC) antigen presentation and, therefore, may provide new options for tumors with low TMB or defects in antigen presentation. Early results with CAR T therapy against brain tumors have shown promise while at the same time illustrating multiple challenges. These include addressing tumor antigen heterogeneity, overcoming an immune-suppressive tumor microenvironment (TME), ensuring sufficient T cell trafficking to the tumor, enhancing CAR T persistence, and avoiding CNS toxicity. In this review, we will present the most recent progress and challenges for CAR T cell immunotherapy in the treatment of brain tumors.
| ENG INEERING TUMOR IMMUNIT Y WITH C AR S

| The design of CARs
Chimeric antigen receptors are synthetic immune receptors that redirect T cells to eradicate tumors through specific recognition of surface proteins expressed on tumor cells. CARs are fusion proteins comprised of three main components: the extracellular domain responsible for antigen recognition, the intracellular domain responsible for signal transmission, and region that links these two components for flexibility, stability, and dimerization potential composed of the extracellular spacer and transmembrane domain ( Figure 1 ). 21, 22 The intracellular domain contains the T cell co-receptor CD3ζ, and second-generation CARs include one co-stimulatory molecule, such as CD137 or CD28, to enhance expansion and persistence. 23 Third-generation CARs contain two costimulatory domains in series with CD3ζ. One of the advantages of CARs is their modular design, which provides the flexibility to adjust the antigen recognition and signaling domains based on the targeted cancer types. Further, CAR T cells can be used as delivery vehicles when paired with constitutively or inducibly expressed chemokine such as IL-12, antibody fragments, or other biomolecules. 24, 25 Optimal CAR design is still an empirical process and highly dependent on antigen-and tumor-specific properties. Innovations in CAR design and its application to the advancement of CAR T cell therapy have been previously reviewed. 26 For brain tumor therapy, we will discuss how CAR design is evolving to address the challenges of tumor antigen escape, the suppressive TME and tumor trafficking.
| CAR T cell manufacture
Chimeric antigen receptors T cell manufacturing processes vary widely across therapeutic platforms, and the final product phenotype represents a critical variable impacting the potency of the therapy. 27 The general workflow for autologous cell transfer begins with collection of patient T cells through leukapheresis followed by, in some protocols, the enrichment of bulk T cells or selection of specific T cell subsets. T cells are then stimulated by engagement of their TCR and costimulatory receptors, typically using anti-CD3 and anti-CD28 reagents. Variations on the T cell stimulation step include use of coated beads, plate-bound antibody, soluble CD3 antibody only, and inclusion of other costimulatory or adhesion molecules (ie, CD2). [27] [28] [29] Following activation, T cells are genetically modified to express the CAR, most commonly through lentiviral or retroviral transduction. The engineered CAR T cells are then ex vivo expanded in media containing common gamma chain (γc)-cytokine cocktails, most commonly IL-2 (eg, combinations of IL-2, IL-7, IL-15, or IL-21) to support T cell expansion. The choice of γc-cytokine and concentration greatly impact the final phenotype of the expanded cells. Most manufacturing platforms utilize IL-2, but there is evidence for advantages of using other cytokines, including IL-15, IL-7, and IL-21. [30] [31] [32] [33] [34] [35] A generalizable principle is that manufacturing processes yielding a less-differentiated memory phenotype with greater mitochondrial fitness generates superior CAR T cell products. [36] [37] [38] Reducing the time of ex vivo culture is one strategy that has been shown to yield more potent CAR T cell products, and most patient-specific products are produced within two weeks or less. 39 Ultimately this process is capable of generating millions to billions of engineered therapeutic CAR T cells ready to be infused back to the patient. A detailed summary of CAR T manufacturing has been reviewed previously. 40, 41 In clinical manufacturing setting of brain tumors, there are many outstanding issues to be addressed, including the following: how intrinsic T cell product variability impacts potency; the effect of concomitant dexamethasone on the quality or quantity of manufactured product; whether certain T cell subsets traffic to the CNS more efficiently; and whether off-the-shelf manufacturing platforms will improve the consistency, timing, and availability of CAR T therapy.
| ADOP TIVE T CELL THER APY: FROM B LOOD TO B R AIN
Clinical success with CD19-CAR T therapies and adoptive cellular therapy (ACT) studies in melanoma, while not initially intended to treat brain tumors, have nevertheless raised optimism for the potential of ACT for the treatment of CNS disease. In trials of ACT for metastatic melanoma, Hong and colleagues reported on a subset of patients (26 of 264) who were retrospectively identified to have had untreated melanoma brain metastases as well as extracranial disease. 42 Remarkably, after treatment with ACT using either autologous tumor infiltrating lymphocytes or lymphocytes transduced to express a T cell receptor targeting a melanocyte-specific antigen, nine patients (35%) achieved a complete response in the brain and seven patients achieved an overall partial response. 42 Clinical experience with CD19-CAR T therapy also serves as a roadmap for CAR targeting of brain tumors. CD19-CARs have demonstrated remarkable clinical outcomes for patients with CD19-positive B cell malignancies, which led to FDA approval in 2017 of the first two CAR T cell therapies: tisagenlecleucel (Kymriah) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL), 43 and axicabtagene ciloleucel (Yescarta) for r/r large B cell lymphoma (BCL). 44 Early phase 1 testing of CD19-CAR T cells excluded patients with CNS involvement, but evaluation of cerebrospinal fluid (CSF) post-therapy revealed that the systemically administered CAR T cells often trafficked to the CNS. In a clinical trial of pediatric patients with r/r ALL, Lee and colleagues were the first to report that CD19-CAR T cells were both detected in the CSF in the majority of patients evaluated, and also capable of eliminating CNS leukemia. 45 Another case report described a patient with refractory BCL that had metastasized to the brain, and this patient had a complete remission of an intraparenchymal brain metastasis after receiving CD19-CAR T cell therapy. 46 While ACT for brain tumors is still in early stages of investigation and clinical responses are often ineffective, these experiences illustrate the potential of T cell therapy to provide clinical benefit for patients with CNS disease, and have generated enthusiasm for furthering the application of this therapeutic approach to brain tumors. Indeed, there are currently F I G U R E 1 Chimeric antigen receptor (CAR) design. CARs are modular synthetic immunoreceptors that consist of a tumor targeting domain fused to an intracellular T cell signaling domain via the extracellular spacer and transmembrane (TM) domains. The tumor targeting domain has been designed and tested against multiple brain tumor antigens including IL13Rα2, HER2, and EGFRvIII ( Table 2 ). The TM domain and extracellular spacer influence effector-target cell interaction by providing flexibility, allowing dimerization to occur, and influencing stability. The cytoplasmic intracellular signaling domain is composed of a CD3ζ activation domain, and is most often paired with cognate T-cell co-stimulatory signaling domains (CD28, 4-1BB, OX40, CD27, and ICOS), which improves CAR T-cell proliferation, survival, and recursive killing Tumor Targeting Domain -Antibody single-chain variable fragment (scFv) or ligand -MHC-independent target recognition -Determines antigen affinity, specificity and antigenindependent signaling Extracellular Spacer and Trasmembrane Domain -Non-signaling -Determines proximity to target cell, flexibility, and dimerization potential -Common spacers: IgG-Fc, CD8h, CD18h
Intracellular Signaling Domain -Costimulation improves CAR T signaling -Common costimulatory domains: CD28, 4-1BB, OX40, CD27, ICOS -CD3ζ directed cytolytic killing
Co-Stim more clinical trials evaluating CAR T cell therapy for brain tumors than any other solid tumor indication ( Figure 2 ). CD19-CAR T clinical experiences have also provided points of caution for neurotoxicity that can be associated with CAR T cells.
The incidence of high-grade neurotoxicity occurs in approximately 12%-32% of patients treated with CD19-CARs across indications, and includes symptoms of delirium, confusion, and seizures. [47] [48] [49] [50] Lethal cerebral edema has also been reported in a handful of patients treated with CD19-CAR T cells in B-ALL and non-Hodgkin's lymphoma, 51, 52 highlighting the life-threatening risks of immune inflammatory reactions in the CNS. The gamut of these neuro- imaging changes, as well as post-mortem brain for correlatives of CRES. 48 This study revealed that patients with severe neurotoxicity demonstrated evidence of endothelial cell activation, including disseminated intravascular coagulation, capillary leakage, and increased blood-brain barrier permeability. The permeable BBB failed to protect the CSF from high concentrations of systemic cytokines, which resulted in brain vascular pericyte stress and secretion of endothelium-activated cytokines. This is supported by other studies demonstrating that CAR-related neurotoxicity is associated with disease burden, high CAR T dose, and cytokine release syndrome (CRS). 53 Norelli and colleagues simulated CAR T cell-mediated CRES in a humanized mouse model with high leukemia burden. 54 Human monocytes were the major source of IL-6 and IL-1 during CRS and CRES, and both toxicities were prevented by monocyte depletion.
IL-1-receptor blockade inhibited both CRS and neurotoxicity in mice,
whereas blocking IL-6 decreased CRS-like symptoms without reducing the incidence of lethal neurotoxicity. Non-human primate models also have demonstrated an association with CD19-CAR-mediated neurotoxicity, proinflammatory CSF cytokines, BBB disruption, and pan T cell encephalitis. 55 The clinical trial experience in CD19-CAR will help inform future trials related to CARs for brain tumors.
Important clinical trial correlates should include pro-inflammatory CSF cytokines measurements, including IL-1 and IL-6, magnetic resolution tomography (MRI) evaluation for BBB disruption, and neuromonitoring. Whether CAR therapy applied to CNS tumors will cause similar problems requires further investigation, but has not been observed to date in initial clinical studies with CAR T cell therapy for GBM.
| INITIAL CLINI C AL E XPERIEN CE WITH C AR T CELL THER APY FOR G B M
Initial clinical experiences with CAR T cells for brain tumors have focused on treating recurrent or refractory GBM in both adult and pediatric patients and targeting a limited set of antigens: IL13Rα2, EGFR variant III (EGFRvIII), and HER2 (Table 1) . These lead therapeutic candidates were selected based on evidence for negligible expression on normal brain and documented expression by GBM. For brain tumors, restricted expression is particularly critical because off-tumor targeting of normal brain can result in lethal toxicity, as has been unfortunately observed with MAGE-A3 TCR-engineered T cells. The therapeutic T cells recognized an off-target epitope of MAGE-A12 expressed in the brain, resulting in lethal neuronal cell destruction and inflammatory responses. 56 Given the risks associated with targeting normal brain tissue and neuroinflammation, caution is required regarding many factors influencing adoptive cell activity, such as cell dose and preparative regimens, as well as the identification of tumor-specific targets. First-in-human clinical trials targeting IL13Rα2, EGFRvIII, and HER2 have elucidated important insights regarding safety and bioactivity that are guiding future translation of CARs for brain tumors.
| CAR T cells targeting IL13Rα2
The first CAR T cells developed and optimized for brain tumors targeted IL13Rα2, a high affinity IL-13 receptor first discovered by Debinski and colleagues to be overexpressed by the majority of GBMs. 57 IL13Rα2 expression has been shown to increase with malignancy grade, to be a prognostic indicator of poor patient survival, and to be associated with gene signatures defining the mesenchymal subclass of GBM. 58, 59 IL13Rα2 is expressed by both glioma stem-like cells (GSCs) and differentiated tumor populations, 60 rendering both malignant subpopulations susceptible to CAR T cell cytotoxicity. Importantly, IL13Rα2 is not expressed at significant levels on normal brain tissue. 59, 61 Our group generated fully human IL13Rα2-CARs with the human IL-13 cytokine for tumor recognition, which represents a distinct F I G U R E 2 Chimeric antigen receptor (CAR) T cell trials for brain tumors vs other solid tumors. Clinical trial count in the United States evaluating CAR T cell therapy for solid tumors as of April 2019. As graphically represented, the largest number of CAR T cell trials for solid tumors is for brain tumors, which include trials for glioblastoma and other malignant gliomas (n = 12), as well as brain metastases (n = 1). Listed trials include those that are pending activation, enrolling patients, and completed TA B L E 1 First-in-human clinical experience with CAR-T therapy for glioblastoma class of CARs utilizing receptor ligands vs antibody scFvs for tumor targeting. Drawing from work on cytotoxin-conjugated IL-13 that defined mutations which increased the specificity of IL-13 for IL13Rα2 over the more ubiquitously expressed IL13Rα1/IL-4Rα complex, an E13Y site-directed mutation was introduced in IL-13. 62, 63 In vitro studies showed that CAR T cells were specific to glioma cells, and consistent with the different affinities of the IL-13(E13Y) mutein for IL-13 receptor forms, the engineered T cell activity was observed only against cell lines expressing IL13Rα2. 63, 64 First-generation IL13Rα2-targeted CARs, termed IL13-zetakine, demonstrated antiglioma activity in vitro and in vivo in mice, 63 and second-generation CAR designs with the inclusion of a 4-1BB costimulatory domain and an optimized spacer domain improved anti-tumor potency more than 10-fold against human GBM xenografts. 64, 65 IL13Rα2-targeted CAR T cells were the first to be clinically were observed, and a subset of patients presented clinical evidence of transient anti-glioma activity. 66 This included increased tumor necrotic volume by MRI and PET, significant reduction in IL13Rα2+ tumor cells, and detection of transferred T cells at tumor microfoci distal from the site of injection. [66] [67] [68] However, first-generation IL-13-zetakine CAR T cell therapy yielded limited T cell persistence, [66] [67] [68] and improvements in CAR design and manufacturing were initiated with the goal of improving therapeutic potency. 64, 69 In 
| CAR T cells targeting EGFRvIII
Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that is genetically amplified and/or mutated in approximately 50% of adult primary GBM, making it an attractive candidate for targeted therapy. 75 EGFR variant III (EGFRvIII), the genetic mutation most commonly found in glioma, has a truncated extracellular domain that leads to constitutive signaling activation and is associated with GBM development and progression. 76 This truncated variant presents a novel, tumor-specific immunogenic epitope for generating scFv-based CAR-targeting domains, and because of its tumor-restricted expression, EGFRvIII is one of the most actively investigated CAR targets for GBM. [77] [78] [79] [80] The NCI published results of a dose escalation study of EGFRvIII For the 18 patients treated, the median survival was 6.9 months and no objective responses were observed, although one patient was reported to have progression free survival (PFS) of 12.5 months, and was still alive at 59 months. 81 This study highlights challenges associated with treating brain tumors with targeted therapy, including the need to better understand the mechanism of action of the therapeutic cells at the tumor site.
CAR T cells in recurrent EGFRvIII+
Researchers at the University of Pennsylvania have also developed a humanized EGFRvIII-specific CAR and showed that it efficiently targeted orthotopically implanted EGFRvIII+ GBM in preclinical models. The scFv was optimized for specificity against EGFRvIII over wild-type EGFR, and showed minimal reactivity to primary human tissue in vitro and to human skin grafts in vivo. 82 This Although the tumor-restricted expression profile of EGFRvIII render this receptor an attractive target, its expression is reported to be unstable throughout the course of disease, 83 increasing the likelihood of antigen-negative escape variants under targeted therapy. For this reason, wild-type EGFR may be a more attractive target for CAR T targeting, given that it is over-expressed in more than 60% of GBM. 84 However, because EGFR is expressed on many normal tissues, including skin, bladder, and liver, there is significant risk of ontarget off-tumor toxicity. To address this concern, antibodies have been generated to target activated and over-expressed EGFR and EGFRvIII. One such selective antibody, mAb806, has been shown to selectively bind EGFRvIII and amplified EGFR. 85 A clinical study of the biodistribution and tumor localization of 111 Indium-EGFR806 antibody in seven patients demonstrated no evidence of normal tissue uptake nor any significant toxicity. 86 An EGFR806-CAR is currently being evaluated in a phase I trial in pediatric solid tumors at Seattle Children's Hospital and will provide important safety information regarding on-target off-tumor toxicity. Other groups have affinity-tuned antibodies to amplified EGFR and EGFRvIII, demonstrating that lower affinity toward endogenous EGFR can improve the specificity of CAR targeting. [87] [88] [89] 
| CAR T cells targeting HER2
Human epidermal growth factor receptor 2 (HER2) is overexpressed in many cancers and well-studied in breast cancer. 90 The majority of GBMs are reported to express HER2, but the receptor is not observed in normal brain tissue (www.prote inatl as.org). 91 Safety considerations regarding targeting HER2, however, are important to note due to the death of the first patient treated with HER2-CAR T cell therapy. The patient received lymphodepleting chemotherapy prior to intravenous (IV) infusion of 10 10 HER2-CAR T cells, a comparatively high dose of transferred cells. 92 The death was speculated to be the result of off-tumor targeting of normal lung epithelial tissue, which triggered cytokine release resulting in respiratory distress and pulmonary edema. This finding raised questions about CAR design and therapeutic safety, particularly of the tumor-targeting scFv, which was based on the high-affinity trastuzumab antibody.
In addition, the CAR costimulatory signaling was produced by both CD28 and 4-1BB in a third-generation design. This clinical experience has prompted the preclinical development of more selective CAR designs, including lower affinity mutants of the trastuzumab scFv, 89 optimization of the trastuzumab-CAR costimulatory domain for lower cytokine production and improved tumor selectivity, 93 and the use of the lower affinity HER2-monoclonal antibody FRP5 for the tumor-targeting domain. 94, 95 An understanding of how HER2-CAR designs impact both safety and anti-tumor potency in the clinic remains under investigation.
To date, the most extensive HER2-CAR T cell clinical experience has been from the Baylor group evaluating the FRP5 HER2-CAR in a second-generation CD28 costimulatory format. 94, 95 HER2-CAR T cells specifically killed HER2-positive GBM cells and CD133-positive GSCs, which have been shown to be resistant to radio-and chemotherapies. Preclinical studies also showed that HER2-CAR T cells do not target HER2-negative cells, and primary endothelial and epithelial cells did not activate HER2-CAR T cells. 95 In studies of the HER2-CAR design, our preclinical work demonstrated decreased cytokine production and improved antitumor efficacy of 4-1BB vs CD28 costimulation. 93 Moreover, ICVdelivered CAR T cells were shown to eradicate tumors implanted in both hemispheres. City of Hope has recently initiated two phase I trials using an optimized HER2-CAR for patients with HER2+ malignant glioma and for patients with breast metastases to the brain (NCT03389230 and NCT03696030, respectively). Given our clinical experience with IL13Rα2-CAR in glioma and preclinical studies evaluating route of delivery, 64, 69, 93 we surmised that locoregionally delivered HER2-CAR may be effective for both primary brain tumors as well as brain metastases. These clinical studies are evaluating locoregional delivery of HER2-CAR T cells to shed light on whether locoregional delivery methods may reduce the potential for systemic toxicity. One important distinction between these two trials is the relatively lower expression of HER2 in glioma compared with HER2-amplified breast cancer, as well as the distinctly different genetic backgrounds and TME. Only with clinical testing and multi-parameter molecular correlative data analysis will we determine how these vastly different tumors respond to the same CAR T treatment.
| Lessons learned from initial clinical experience with CAR T cells for GBM
The clinical trial experience of IL13Rα2-, EGFRvIII-, and HER2-CAR T cells against GBM provide initial evidence of the safety and antitumor activity of CAR T cell immunotherapy in patients with malignant brain tumors. Clinical results published from studies support the safety of targeting these GBM-associated antigens in the CNS.
Also encouraging, a subset of patients appeared to show benefit from treatment. After treatment with IL13Rα2-CAR T, one patient had a CR lasting about 7.5 months, which was remarkable given the aggressive multifocal nature of his recurrent disease. After treatment with EGFRvIII-CAR T cells on the clinical trial NCT02209376, one of 10 patients had extended stable disease and remained alive more than 18 months, 80 and on the NCT01454596 trial, one patient also had extended PFS of 12.5 months. 81 Finally, after HER2-CAR T treatment, 1 of 17 patients had a partial response and seven of 17 patients had stable disease (three extended stable disease). More investigation is needed to determine whether these patients were more responsive to therapy due to underlying differences in tumor biology and immune landscape.
Analysis of tumor tissue after IL13Rα2-or EGFRvIII-CAR T cell infusions provide evidence for antigen loss as a pathway of therapeutic escape. Recurrent tumors in two patients treated with IL13Ra2-CARs (NCT02208362 and NCT00730613) showed lower levels of the IL13Rα2, and in patients tested on NCT02209376, five of seven had lower levels of EGFRvIII and two of seven patients had undetectable antigen. Although these results may indicate tumor cell killing by CAR T cells, they also illustrated that antigen loss must be overcome in developing next-generation CAR therapies (discussed in detail below). These initial clinical experiences also highlight the potential interplay between the host immune system and CAR T cells in the CNS. In response to IL13Rα2-CAR T therapy, the TME had increased CD3+ CD14+ CD15+ immune cells in addition to inflammatory cytokines after each loco-regional CAR infusion. In response to EGFRvIII-CAR T therapy, the TME had increased IDO, FOXP3, IL-10, PD-L1 markers, and TGFβ. Understanding the determinants of response will help us understand who will benefit most from treatment, and importantly, may help us to modify adoptive immunotherapies to overcome obstacles presented by the tumor and TME.
| OVERCOMING TUMOR HE TEROG ENEIT Y
| Understanding the heterogeneity of brain tumors
To expand the repertoire of antigens for CAR T cells and identify optimal targets to limit antigen escape of brain tumors, an understanding of the complexity of tumor heterogeneity is essential. Tumor cell plasticity has been rigorously investigated as a major factor complicating cancer diagnosis and treatment, as well as mediating therapeutic resistance. 98 Molecular and cellular heterogeneity manifests as one of the most notable characteristics of brain tumors, especially
GBMs. 99 The past two decades have seen the evolution of GBM genetic characterization, leading to the identification of subtypes based on mutations in key oncogenic pathways and differences in gene expression profiles. 100 The existence of GBM subtypes helps explain the different responses to therapies, and some of the genetic signatures (eg, IDH1/2, MGMT, H3K27) have been used to guide diagnosis and treatment. 3 The switch between subsets has also been shown to associate with tumor relapse. 101 However, the complexity of brain tumor heterogeneity appears to go beyond the differential expression of certain genes and molecular subtypes.
Classifying GBMs into subtypes has focused on genetic signature at the whole-tumor level, thereby simplifying the substantial intratumoral heterogeneity of GBMs. Independent studies have elucidated the differential gene expression patterns in distinct anatomic regions within a tumor. 102, 103 More specifically, the leading-edge of GBMs was shown to display a proneural-like signature, while the tumor core appeared more mesenchymal-like. 103 The intratumoral heterogeneity of GBMs was further illustrated by cellular and genomic analysis at the single-cell level. Meyer and colleagues profiled individual tumorigenic clones from patient-derived GBM cells, identifying pre-existing clones harboring the potential to resist anti-tumor treatments such as TMZ. 104 The results indicated that pre-treatment tumor heterogeneity might be responsible for clonal selection toward recurrence. In addition to isolating and characterizing subclones from GBM tumors, other studies used an approach to directly sequence primary tumor cells with advanced single-cell RNA-sequencing (scRNAseq) technologies. 105, 106 All of these stud- Intriguingly, scRNAseq has also revealed a nonautonomous regulatory mechanism of brain tumor heterogeneity. In a comparison between the single-cell transcripts of IDH-mutant astrocytomas and oligodendroglioma, no significant difference in glial lineage composition was found, suggesting a common malignant developmental re-programming; instead, the TME signatures were distinct between the two types of tumors. 106 Further, higher grade astrocytomas and oligodendrogliomas were found to associate with the enrichment of macrophage over microglia. 106 In GBMs, immunological signatures were found to differ between subtypes, with the mesenchymallike tumors harboring an enrichment of immune-related genes. 107 Moreover, compared with primary GBMs, recurrent GBMs demonstrated an altered composition of infiltrating immune cells, particularly a noted decrease in monocytes. 101 Together, these findings illustrate the heterogeneity in brain tumors at multiple levels including inter-patient, intratumoral, and within the TME.
Tumor heterogeneity has complicated CAR T cell therapy for brain, as well as other tumors. Indeed, even with the success of CD19-CAR T cell therapy against B cell malignancies, patients with complete responses often relapsed following therapy with undetectable CD19 antigen. 108 Further, the loss and/or decrease in target antigen expression has also been observed in CAR T cell clinical studies of GBM. 66, 69, 80 We have reported examples of IL13Rα2 loss/ decrease in relapsed/recurrent tumors following IL13Rα2-CAR T therapy. 69 Likewise, in a study using EGFRvIII-CAR T cells, 4 of 6 of resected tumors post CAR T cell infusion displayed significant downregulation of EGFRvIII. 80 Therefore, advancing CAR therapy against brain tumors requires strategies to minimize antigen escape caused by tumor heterogeneity.
| Discovering new targets
Tumor antigen heterogeneity in brain tumors leads to resistance against CAR T cells, pointing to the need for an expanded repertoire of targeted antigens. The success of CD19-CAR T cells highlight the criteria that an ideal CAR target should be widely expressed across different tumors and intratumoral cellular subsets. However, finding such antigens in brain tumors has been challenging since brain tumor cells express many markers which are shared by regions of the normal brain (eg, CD133, CD44, Nestin, GFAP), and the off-tumor targeting consequences in the CNS are far less tolerable than most other parts of the human body. Therefore, the discovery of CAR T cell targets in brain tumors requires consideration of the breadth and specificity of tumor-antigen expression.
In addition to targets mentioned in the sections above (IL13Rα2, EGFRvIII and HER2), other antigens are under investigation for CAR therapy in brain tumors ( Table 2) . Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) was found to be over-expressed in GBMs, and to enhance tumorigenesis and migration. 109 An EphA2
inhibitor showed anti-tumor effects in mouse models of pancreatic ductal adenocarcinoma. 110 EphA2-targeted CAR T cells with second-or third-generation CAR designs were able to eradicate GBMs in preclinical studies, yet with limited persistence. 111 EphA2-CAR T cells are currently being evaluated in GBM patients, but no clinical results have been reported (NCT02575261).
Another antigen that has been intensively investigated as a CAR target is the disialoganglioside GD2. GD2 was found to be expressed in a class of pediatric brain tumors called diffuse midline gliomas B7-H3 (CD276) is an immune-checkpoint molecule, which negatively regulates T cell activation, 114, 115 and is also associated with tumor migration and invasion. 116 An analysis on the TCGA database showed that B7-H3 expression is up-regulated particularly in highgrade gliomas. 117 Another study screened a panel of primary GBM samples representing various molecular subtypes, and identified Chondroitin sulfate proteoglycan 4 (CSPG4, also known as neuron-glial antigen 2, NG2) to be widely expressed across these tumors. 119 Moreover, CSPG4 expression can be induced by the immune-stimulatory cytokine TNFα, which is produced during CAR T cell anti-tumor responses thereby making tumor antigen escape less likely. 119 Glioblastoma tumors contain specific subsets with the characteristics of self-renewal and tumor regeneration, and studies have shown these GBM stem-like cells (GSCs) to mediate resistance against radiotherapy and chemotherapy. 120 The ability to eliminate GSCs, therefore, is essential for GBM-targeting therapies to minimize tumor recurrence. On the one hand, using the strategy to enrich and expand tumor spheres from resected GBMs, 121 different studies have proven the CAR T cells targeting IL13Rα2, HER2 and
EGFRvIII are able to eliminate differentiated GBM cells as well as GSCs, 60, 78, 95 indicating that CAR-mediated cytotoxicity is not dependent on the "stemness" of GBM cells. On the other hand, CAR T cells have been developed against CD133 which is one of the surface markers of cancer stem cells including GSCs. 122 CD133-CAR T cells have shown preclinical cytotoxicity against patient-derived GSCs, 123 as well as anti-tumor response in patients with tumors in liver, pancreas, and colon. 124 However, CD133 is also expressed in neural stem cells, 125, 126 thus raising the safety concerns of applying CD133-CARs to GBM patients.
As an alternative to antibody-based CAR designs, tumor-binding peptides can also be exploited as the tumor-targeting domain of a CAR. The utility of tumor-binding peptides has already been demonstrated clinically for both diagnosis and treatment of cancers. 127, 128 Recently, we have developed a GBM-targeting CAR bearing the scorpion-derived peptide chlorotoxin (CLTX). 129 Studies have confirmed the specificity of CTLX binding to GBM, demonstrating its exquisite ability to distinguish between tumor and normal brain tissues. 130 A fluorescently labeled CLTX agent is currently under clinical investigation as a tumor imaging agent to enable more precise surgical resection. 131, 132 When incorporated into CARs, CLTX redirects T cells for specific tumor recognition with negligible off-target effects on normal cells or tissues. 129 The development of a CLTX-CAR has shown the potential for peptide binding to redirect CAR T cell cytotoxicity.
Further, the pool of brain tumor antigens amenable to CAR T cell targeting is expected to expand beyond membrane-associated proteins. Chheda and colleagues discovered a shared neoantigen across DIPG patients derived from a mutation in the H3.3K27. 133 Stimulating HLA-A2+, CD8+ T cells with the mutated peptide generated a TCR clone which, when expressed on T cells, mediated cytoxicity against tumor cells harboring the same mutation. 133 Moreover, some recent studies have developed CARs against soluble proteins, 134, 135 indicating the potential to target brain tumor-specific secreted factors.
These efforts to expand the identification of tumor targets for GBM and other brain tumors provides new options for CAR T cell therapeutic development. Of course, the critical benchmark will be to establish safety for these new antigens in well-designed clinical trials (see below). Once safety is established, tremendous opportunities become available to utilize CAR T cells targeting one or several of these antigens, against a wide-range of brain tumors as well as a broader range of intratumoral cell subsets. Meanwhile, the capability of CAR T therapy against GSCs may further reduce tumor recurrence.
| Addressing antigen escape by advancing CAR designs
Despite the emergence of new targets to direct CAR T cell therapy against brain tumors, recurrent tumors will likely still be able to bypass monovalent CAR T cells through downregulation of the targeted antigen or emergence of antigen negative clones. Consequently, one strategy against antigen escape is to extend the conventional single-targeted CAR design to encompass bispecific targeting domains, rendering the recognition of either of two antigens sufficient to trigger T cell activation. 136 The design of these "OR-gated" CARs may increase safety concerns for the potential of non-tumor targeting.
Therefore, the targets for bispecific CARs are generally selected from the pool of well-characterized tumor-specific antigens or after safety of monovalent CAR-targeting has been established. One of these examples is CD22, another cell surface marker for normal and malignant B cells in addition to CD19. 137 With CD22 single-targeted CAR T cells well tolerated in patients with B-ALL, 138 CD19/CD22 bispecific CAR T cells are currently under investigation in multiple clinical trials (NCT03448393, NCT03233854, NCT03241940).
Additionally, CD20, another B cell surface marker, has been combined with CD19 to generate a bispecific CAR which eradicates lymphomas expressing either antigen in preclinical models. 139 Likewise, designs of bispecific CARs against GBMs have focused on the antigens well characterized in preclinical and clinical studies, including IL13Rα2, HER2, and EphA2. Hedge and colleagues developed a CAR with bispecific targeting of IL13Rα2 and HER2. 140 Using an orthotopic GBM xenograft model expressing both antigens, the authors showed that bispecific CARs were able to control the tumors for approximately 1 month, while single-targeted CAR treatment did not lead to tumor regression due to antigen escape. 140 This approach was further extended with a third targeting domain against EphA2. 70 However, tumor relapse was found in all preclinical studies of these CARs, with the loss of all targeted antigens. 70, 140 These studies raise questions as to the minimal number of targets and optimal combinations to "box-in" tumor antigen escape.
The optimal structural design of bi-or tri-specific CARs is still an open area of investigation and highly dependent on the antigens being targeted and structural consideration for the antibody or ligand binding domains. Currently two different structural designs have been tested for "OR-gate" targeting strategy. The "tandem" design puts the heavy and light chains of each single-chain variable fragment (scFv) in a sequential order, 139 while the "loop" design resembles the structure of bivalent antibodies. 141 The comparison between different "OR- Multi-antigen targeting can also be achieved by expressing two CAR molecules on the same T cell, or mixing different singletargeted CAR T cells. 136 Both approaches have been investigated in preclinical models of relapsed B-ALL by co-targeting CD19 and CD123. 143 Clinical experience with sequential infusion of CD22-and CD19-CAR T cells into B-ALL patients provide evidence that combining different CAR products is a feasible strategy. 144 Notably, the safety and toxicity might be easier to monitor when using mixed CAR T cells given the experience with individual single-targeted CAR T products. Other studies, however, suggest that bispecific CAR T cells are more potent than pooling single-targeted CAR T cells both in vitro and in vivo, possibly due to local competition effects. 139, 140 The development of "universal CARs" is also expected to significantly benefit the challenge of tumor heterogeneity. These designs use adapters to connect CAR with the targeted antigens, thus allowing for antigen switch without re-engineering T cells. 145, 146 Tremendous progress has been made in the identification of tumor-specific antigens and the development of novel CAR designs against brain tumors. While combinatorial targeting has shown promise in addressing tumor heterogeneity, it remains under investigation with regard to optimizing the number and combination of targeted antigens. Most of the uncertainty comes from the lack of understanding on the dynamic changes of tumors following immunological attack. Therefore, uncovering the evolution of brain tumors following CAR treatment, especially the alterations in intratumoral subpopulations at single-cell resolution, will provide valuable information to guide CAR T cell therapy and overcome tumor heterogeneity. While the notion that the CNS is immunologically "privileged" has been recently challenged, the unique anatomical features of the CNS pose challenges that may impede the ability of T cells to recognize and respond to antigens within the brain. The molecular events required for immune recognition of brain tumors are still under investigation; however, as evident in the settings of autoimmune diseases such as multiple sclerosis, T cell immunosurveillance occurs in the CNS. In fact, several studies have identified chemokines and adhesion molecules that may be critical for T cell trafficking into the brain. 147 Identifying mechanisms that induce T cell surveillance and trafficking and implementing these into CAR T design or as adjuvant therapy could improve the systemic anti-tumor response to brain tumors (see below).
| C AR T CELL S AND THE SUPPRE SS IVE MICROENVIRONMENT OF B R AIN TUMOR S
| Unique aspects of TME of GBM
In addition to the anatomical features that limit T cell infiltration, glioma intrinsic factors based on the mutational profile and gene expression patterns also contribute to the suppressive TME. Gliomas exhibit a complex and unique mutational signature that can contribute to the immunosuppressive landscape. A study by Kohanbash and colleagues has shown that mutations in isocitrate dehydrogenase genes IDH1 and IDH2 in glioma cells suppress STAT1 expression, leading to reduced accumulation of CD8 T cells, type 1-associated effector molecules, and chemokines such as CXCL10, thereby shaping the tumor immune environment. 148 In line with these findings,
Berghoff and colleagues demonstrated that IDH-mutant gliomas exhibited significantly lower rate of T cell infiltration compared to IDH-wildtype. 149 Tumor-intrinsic mechanisms can dictate the TME landscape; therefore, therapeutic interventions are needed to convert gliomas into an immunologically responsive microenvironment.
The glioma TME is characterized by low nutrients and hypoxic regions. The lack of nutrients, especially essential amino acids such as tryptophan, lysine, and arginine, is responsible for autophagic processes and stress responses that negatively impact T cell function. 150 Enzymes such as indoleamine 2,3 dioxygenase (IDO) and arginase (Arg1) catabolize essential amino acids tryptophan and arginine, respectively. These enzymes are highly expressed by tumor cells and/or myeloid cells within the TME and can cause T cell suppression. In fact, kynurenine-a metabolite of L-tryptophan-has been shown to reduce memory CD4 T cell survival. 151 Studies by our group and others have shown that Arg1-expressing tumor-associated myeloid cells exhibit suppressive activity against T cells. 152, 153 Lactic acid, a by-product of tumor metabolism, has been found to suppress T cell proliferation and production of cytokines. 154 Furthermore, immunosuppressive factors such as prostaglandin E2
(PGE2) and adenosine, released in large quantities by tumor cells and macrophages in hypoxic conditions, can inhibit T lymphocyte proliferation by activating protein kinase A (PKA). A study by Newick and colleagues demonstrated that inhibiting PKA enhanced trafficking and efficacy of CAR T cells. 155 Increased hypoxia-inducible factor-1 alpha (HIF-1α) activity and hypoxia in tumor tissues have been correlated with poor prognosis of cancer patients. 156 Hypoxia has been shown to upregulate PD-L1 expression by tumor cells and to promote tumor proliferation. 157 while increasing the suppressive activity of tumor-associated myeloid cells, 158 resulting in impaired CD8 + TIL-functioning. Together, these data show that hypoxia and metabolic pathways may contribute to reduced immune responses.
Therefore, targeting and altering metabolic components in the TME could enhance CAR T therapy.
Tumor-associated myeloid cells represent the dominant immune population in the glioma TME. Tumor-associated myeloid cells are frequently polarized toward a pro-tumoral phenotype, and in combination with regulatory T cells, produce immunosuppressive cytokines/ligands including TGFβ, IL-4, IL-10, Arg1, IDO and PD-L1. 159 Strategies to limit myeloid recruitment or reprogram the myeloid populations have been proven beneficial. 160 In preclinical studies, blockade of colony stimulating factor receptor (CSFR; a receptor exclusively expressed by myeloid cells) on glioma xenografts enhanced anti-tumor response to radiotherapy by reducing the recruitment of bone marrow-derived macrophages. 161 Additionally, inhibiting STAT3, a key regulator in pro-tumoral macrophages, significantly reduced macrophage polarization in patients with malignant glioma. 162 Furthermore, treatment with tyrosine kinase inhibitors such as sunitinib that inhibit STAT3 signaling pathways, induced cancer cell apoptosis and reversed immunosuppressive cytokine profile. 163 These studies suggest that selective targeting of immunosuppressive myeloid cells in the TME may synergize with CAR T therapy.
In addition to suppressive immune cells in the glioma TME, soluble factors secreted by both tumor and tumor-associated immune cells can inhibit immune-mediated cytolytic responses. Specifically, TGFβ has been found to inhibit T cell cytotoxic activity and promote regulatory T cell generation. TGFβ has been implicated in resistance to PD-L1 therapy by contributing to T cell exclusion in the tumor bed. 164 Targeting the TGFβ pathway has been shown to improve anti-tumor activity in several tumor models including gliomas. 165 Glioma-associated IL-10, a potent anti-inflammatory cytokine secreted by myeloid cells and a subset of CD4+ T cells, 166 has been shown to induce STAT3 in macrophage and dendritic cells, 167 
| Approaches to improve CAR T cell activity
| Engineering resistance into CAR T cells
Various approaches have been implemented to overcome the suppressive effects of cytokines in the TME. In the context of CAR T therapy, several studies have investigated "the reverse approach," which consists of inhibiting immunosuppressive cytokines or con- 
| Engineering cytokine support into CAR T cells
Chimeric antigen receptors T cell persistence and survival is of utmost importance especially in solid tumors. Longer persistence of CAR T cells posttreatment has been associated with better clinical response. 113 Our team has modified the manufacturing to select for T cells with a less differentiated phenotype. 69 Our group and others have evaluated reduced ex vivo culture duration and addition of cytokines such as IL-7 and/or IL-15 to culture conditions. 30, 31 Certain cytokines support survival and expansion of T cells, and (NCT02498912). 179 The use of engineered CAR T cells to deliver a range of cytokines, and their potential to support not only the T cell persistence and function, but also to remodel the TME to be anti-tumorigenic is of importance, especially in the context of solid tumor therapies.
| Combination therapies to augment CAR T cell function
Combination therapies designed to overcome the hostile glioma environment while improving CAR T cell persistence and function may be a promising strategy. Targeting immune inhibitory molecules such as PD-1, CTLA-4 and PD-L1 has been the focus of many studies as a potential therapy that could enhance CAR T cell efficacy. 180 Combining CAR T cell therapy with checkpoint blocking agents could overcome impediments to T cell infiltration and functionality.
Several preclinical studies have shown benefit in blocking PD- 1 181 or CTLA-4 182 in murine glioma models. Importantly, two recent clinical reports have shown benefit for neoadjuvant anti-PD-1 immunotherapy in promoting survival 20 and (IL13Rα2-CAR T + Nivolumab). Although, the clinical impact of CAR-T cells combined with checkpoint inhibitors in GBM is still unknown, results from these trials will provide important information regarding safety, feasibility, and potential anti-tumor activity.
Oncolytic viruses are also promising agents for the treatment of solid tumors such as gliomas. Oncolytic viruses can specifically target cancer cells, while sparing normal cells, and the resulting tumor lysis can release danger signals and stimulate immune system. 185 Furthermore, oncolytic viruses can be genetically modified to express therapeutic transgenes to target a suppressive TME, potentially synergizing with CAR T therapy. Indeed, studies have reported enhanced CAR T cell efficacy by combining oncolytic viruses expressing either cytokines, chemokines, or an anti-PD-L1 minibody against solid tumors in pre-clinical mouse models. 186 Additional promising combinatorial approaches include agonistic antibodies specific for the 4-1BB costimulatory receptor, 187 which can directly activate CAR T cells. Vaccines in a form of glioma-associated antigens or dendritic cell loaded with mRNA or tumor lysate have been used for primary brain tumors, 188 and could also synergize with CAR T therapy to overcome tumor heterogeneity and induce an endogenous immune response.
| Combining standard-of-care radiation therapy plus CAR T cells
Radiation therapy has long been an important component of standard-of-care management of brain tumors. Evidence for potential synergy of CAR T and radiation therapy lies in the retrospective clinical series and preclinical models of ICI and stereotactic radio-surgery (SRS). Retrospective meta-analysis of patients with melanoma and non-small cell lung cancer brain metastases has demonstrated improved outcomes of combined vs sequential ICI and SRS. 189 Preclinical orthotopic glioma models also have demonstrated efficacy of combination ICI and SRS. 190 Mechanisms by which radiation promotes immunologic memory are under investigation. Preclinical studies have demonstrated that radiation alters the TME to potentiate an adaptive immune response. Tumor irradiation functions as an in situ vaccine because it results in the release of tumor-associated antigens, which activate antigen presenting cells to migrate to draining lymph nodes where they prime cytotoxic CD8+ T cells to generate an adaptive immune response, 191 including recruitment of endogenous TILs and enhanced TCR expansion. 190, 192, 193 Specifically, high dose tumor irradiation increases T cell priming due to cross-presentation of tumor peptides via MHC class I pathway.
Recent studies have shown hypofractionated radiation ( 
| G E T TING C AR S TO G O: C AR T CELL TR AFFI CK ING TO B R AIN TUMOR S
| Anatomical considerations for T cell trafficking beyond the blood-brain barrier (241)
Brain tumors pose unique obstacles for T cell homing due to the selective properties of the blood-brain barrier (BBB) and the blood-CSF barrier (BCSFB), which strictly regulate immune cell entry to the brain. Much of what is known about immune cell infiltration into the brain is derived from models of infection or experimental autoimmune encephalomyelitis (EAE). 197 These barriers regulate extravasation through postcapillary vesicles and limit immune entry in the brain or CSF due to the presence of endothelial cell layers with tight junctions and astrocyte foot process known as glia limitans. 198, 199 From circulation, T cells must first adhere to vascular endothelium via a multitude of integrins, adhesion molecules, and chemokines. 198, 199 Activated T cells, but not naive or resting memory T cells, 200 can be recruited beyond the BBB in the absence of inflammation although CD8 T cells require the presentation of MHC class I antigens on luminal endothelium. 201 Understanding how to best ensure optimal trafficking of CAR T cells to brain tumors remains an active area of investigation, and we will summarize some of the considerations below.
| Route of delivery of CAR T cells for brain tumor therapy
One key question for the advancement of CAR T cell therapy for brain tumors is the choice of delivery route and whether systemic or locoregional delivery is more advantageous, particularly because brain tumors are unique in that they are regionally localized and primary brain tumors such as GBM rarely metastasize outside the CNS. 202 Systemic delivery, whereby CAR T cells are given intravenously (IV), is the most common delivery approach for hematological and solid cancers. For IV delivery, cryopreserved cells can be thawed at bedside and infused directly without the need for reformulation or a delivery device. As reviewed above, melanoma-targeted and CD19-CAR T cells delivered systemically have been shown to traffic to the brain and eliminate malignant disease. 42, 45, 46 However, in both of these clinical settings, the adoptively transferred cells were activated in the periphery due to the presence of disease. Since acti- in orthotopic models of breast cancer brain metastases. 93 Similarly,
ICT administered IL13Rα2-CAR T cells resulted in long-term survival in orthotopic GBM models, whereas IV delivery provided no significant benefit over mock transduced T cells. 64 When comparing locoregional delivery routes in a multifocal GBM model where tumors were implanted on both hemispheres, ICV exhibited improved targeting of multifocal disease. 64 In fact, preclinical studies in which CAR T cells were labeled with the radionuclide 89 Zr and followed by PET imaging in mice, we show that CAR T cells delivered into the brain parenchyma remain localized in the brain, whereas ICV-delivered cells distribute throughout the CNS over 6 days of monitoring by PET (Figure 3 ). 205 Indeed, direct infusion into the CSF via intraventricular delivery achieved a complete clinical response in a patient with multifocal disease, including a distal lesion in the spine, 69 illustrating the surveillance of CAR T cells throughout the CNS.
Locoregional CNS delivery of CAR T cells may also reduce the risk of systemic toxicities associated with the therapeutic cells. For instance, in clinical trials of EGFRvIII-and HER2-CAR T cells, 81, 92 high-dose peripheral (IV) infusion increased the risk of serious pulmonary toxicities, and in the most severe cases resulted in death.
Locoregional delivery is expected to limit intravenous first-pass pulmonary toxicity as well as off-tumor targeting of other systemic tissues. Together these studies suggest that locoregional delivery may improve trafficking, infiltration, and safety of the adoptively transferred cells for the treatment of brain tumors. However, further clinical testing is required to understand how delivery route impacts both safety and patient outcomes.
| Engineering CAR T cells for improved tumor tropism
One strategy to improve T cell trafficking and infiltration is to engineer the cells to express proteins that facilitate tumor tropism. This requires an understanding of the mechanism of T cell extravasation into the brain parenchyma as well as characterization of vascular properties of the specific brain tumor. The interactions between chemokines and their corresponding chemokine receptors in T cells have been studied extensively, 206 and research is underway to apply these fundamentals to CAR T cells.
Engineering CCL17, and CCL21, which have all been associated with glioma. [208] [209] [210] [211] Despite this connection, engineered chemokine receptors have not specifically been evaluated in CAR T cells for the treatment of brain tumors. CCL2 is also produced by the glioma microenvironment to recruit both Treg and myeloid-derived suppressor cells. 212 manipulating tumor chemokine release, we have demonstrated the tumor tropism of adoptively transferred T cells to GBM lines expressing CCL2, which is a ligand for CCR4. 213 Similar to CCR4, CCR2 is a receptor for CCL2, is poorly expressed on activated T cells (<7%), and its addition in CAR T cells has been shown to increase efficacy in neuroblastoma and melanoma models. 214, 215 Other lymphocyte models have leverage chemokines to increase tumor accumulation with the introduction of receptors such as CXCR4, 216 CXCR1, 217 CXCR2, 218, 219 CCR7, 220 and CX3CR1. 221 Additional targeting of endothelial adhesion molecules or vascular cytokines upregulated in brain tumors could also be a worthwhile approach to enhance CAR T cell accumulation at the tumor site. 178, 222 To improve cell localization, chemokine receptor-engineered T cells should be designed for the chemokine signaling unique to each tumor. Such strategies to improve tumor trafficking are important, as preclinical models suggest that trafficking can often be highly inefficient with only a minor fraction of the adoptively transferred cells infiltrating the tumor. 205, 215 When combined with computed tomography (CT) or MRI, the sensitivity of nuclear imaging is co-registered with anatomical detail.
| Imaging of T cell trafficking
MRI also enables additional diagnostic modes based on the pulse sequences, especially in the context of blood perfusion and diffusion in brain tumors. 224 Researchers have used these imaging modalities for tracking cells with techniques for ex vivo labeling as well as in vivo detection of cells using reporter genes or radiolabeled antibodies.
The first study to image CAR T cells for brain tumors evaluated first-generation IL-13-zetakine CAR T cells that were engineered the co-express the herpes simplex virus type-1 thymidine kinase reporter gene (HSV1-tk) in a patient with GBM. 67, 68 Cellular expression of HSV1-tk enabled T cell detection based on uptake of the radiolabeled nucleoside analog 9-[4-[ 18 F]fluoro-3-(hydroxymethyl)butyl]guanine ( 18 F-FHBG). HSV1-tk and its variants have also been used preclinically for studying CAR T cells trafficking. [225] [226] [227] However, the immunogenicity of HSV1-tk has also been reported in the clinical setting. 228, 229 To reduce the risk of immunological rejection, several reporter systems using human genes as non-immunogenic alternatives are being evaluated preclinically to study the trafficking of T cells in mice. 230 In direct comparisons of the reporter systems in T cells, [231] [232] [233] human deoxycytidine kinase (dCK) mutants have shown high relative sensitivity and selectivity over native human dCK. This imaging strategy enables longitudinal imaging sessions yielding signal which correlates with the number of metabolically active cells present, but is limited by tissue permeability of the probe and background uptake of the nucleoside in surrounding tissue. Because these radioactive nucleoside probes have poor BBB penetration, 234 they may not be useful for imaging dCK expressing cells beyond intact BBB as distribution at regions other than disrupted tumor vasculature will be limited.
As an alternative strategy, approaches to directly label cells with radionuclide ex vivo are being developed which enable cell detection with PET imaging after infusion. 111 In-oxine has specifically been used to image the tumor tropism of antigen-specific T cells in preclinical models 235 and patients. 236, 237 This approach is the current clinical standard for imaging cells and platelets with SPECT, where lipophilic metal complexes passively diffuse across cell membranes in a rapid and efficient manner. 238, 239 Recently adopted for PET, 240 we imaged 89 Zr-oxine-labeled CAR T cells in both subcutaneous prostate and intracranial glioma models. 205 more recently applied to the tracking of endogenous T cells 242, 243 or cells with engineered antigen tags. 244, 245 To reduce signal background and circumvent issues with BBB permeability, these antibodies could be used for ex vivo pre-labeling of cells to study initial trafficking 246 as long as the antibody stays cell-associated and radionuclide half-life is permissible. In comparison to passive labeling mechanisms like 89 Zr-oxine, prelabeling with antibody uses the antibody binding affinity while potentially reducing cell damage by localizing radionuclide to the cell surface prior to any receptor internalization. Another approach utilizes the metal binding properties of DOTA after the introduction of a membrane-bound single-chain fragment (scFv) into T cells, which binds to DOTA-lanthanide complexes (DAbR1). 247 More studies are required to determine which of these methods will be most effective in imaging CAR T cell therapy for brain tumors, given the limitations of antibodies permeating the BBB and the sensitivity required for tumor visualization. Taken together, prelabeling techniques should be utilized when sensitivity and initial trafficking is most valuable while infused antibodies and reporter genes are best for multiple imaging sessions and signal which correlates with live cell numbers. Future combinations of these techniques could yield more comprehensive information regarding T cell trafficking into the brain.
| FROM B EN CH TO B EDS IDE: CLINI C AL TRIAL CONS IDER ATIONS
This is an auspicious time for the field of immunotherapy, with opportunities to advance brain cancer treatment through comparing experiences and ideas across many adoptive cellular platforms.
Clini caltr ials.gov lists more CAR T trials for brain tumors than any other solid tumor indication ( Figure 2) . The majority are for malignant glioma (12 of 13), but the extension to metastatic tumors in the brain has begun with the first trial targeting brain metastases (NCT03696030). Five of the 13 trials have been performed at City of Hope: two completed trials in recurrent GBM targeting IL13Rα2, and 3 trials currently enrolling for either IL13Rα2+ or HER2+ GBM, or HER2+ breast metastasis in the brain (Table 1) . Our experience has shaped our trial designs, which are described here in the context of the ideas presented in this review. City of Hope's approach of locoregional delivery and repeat dosing is intended to prioritize for both patient safety and maximum therapeutic benefit. As discussed above, our preclinical studies suggest that locoregional delivery of CAR T cells outperform systemic IV delivery, so our trials have prioritized delivering CAR T cells directly into the tumor or resected tumor cavity (ICT) and/or into the CSF via the lateral ventricle (ICV). The dosing regimen splits the intended total cell dose over 3 to 4 weekly infusions. Splitting the intended total dose into smaller doses delivered weekly is anticipated to minimize safety risks compared with a single bolus intracranial dose, which may cause unintended inflammatory toxicities, including CRS. Multiple or split dosing regimens have been used previously to reduce risk of infusion-related toxicities. 248, 249 Repetitive dosing also affords a larger total dose of cells, and is intended to introduce functional CAR T cells over a longer timeframe, thereby extending the therapeutic window in the immunosuppressive TME. Temozolomide (Temodar [TMZ]) is a DNA alkylating chemotherapy that is routinely used for standard-of-care management of GBM. 250 A common side-effect of TMZ is bone marrow suppression and lymphopenia. 251 In the context of CAR T therapy, preclinical models have demonstrated lymphodepleting pre-conditioning with a dose-intensified regimen of TMZ (TMZ-DI), but not standard TMZ dose regimens. In a syngeneic mouse model of GBM, TMZ-DI pretreatment prompted enhanced EGFRvIII-CAR (IV-administered) expansion and persistence in circulation, as well as tumor eradication. 252 Based on these findings, an ongoing EGFRvIII-CAR T trial at Duke University (NCT02664363) is utilizing TMZ-DI as a preconditioning lymphodepleting regimen. The dual use of TMZ for the treatment of GBM and for lymphodepleting pre-conditioning is an attractive strategy, as lymphodepletion prior to adoptive transfer of T cell-based immunotherapies has been shown to be essential for effective TIL, TCR-, and CAR-engineered T cell anti-tumor activity for systemic cancers when the therapeutic cells are delivered IV. While it is reasonable to assume that lymphodepletion will also augment CAR T cell clinical responses for brain tumors, particularly for IV delivery, its therapeutic benefit in the context of brain tumors requires further clinical validation, since most clinical studies to date have not included lymphodepleting regimens. Additionally, for the two reported EGFRvIII-CAR clinical trials, the NCI study that included lymphodepletion pre-conditioning (Fludarabine + Cyclophosphamid e) and systemic IL-2 cytokine support (NCT01454596) 81 did not show significantly improved CAR T cell persistence, expansion, or patient outcomes compared with the University of Pennsylvania study that did not include lymphodepletion (NCT02 209376). 80 While this could be due to many factors, such as CAR design, target selection, and patient enrollment, it highlights the need for further clinical assessment of the role lymphodepletion in the application of CAR T cells for brain tumors, particularly for locoregional delivery.
| CAR T cell trials at City of Hope
| Concomitant medicines
Dexamethasone (Dex) is a brain-penetrant steroidal anti-inflammatory used often in the glioma setting to alleviate tumor-associated brain swelling. Dex is also highly toxic to immune cells including T cells, which may limit the CAR T cell efficacy. In particular, Dex is known to inhibit priming of T cell immune response by dendritic cells, and was shown to be deleterious to vaccine trials for GBM at very low levels. 10 In preclinical mouse models, intratumorally delivered CAR T cells were functional with low-levels of Dex (1 and 0.2 mg/kg), but were strongly suppressed by high levels (5 mg/kg). 64 Further, CD19-CAR T cell trials report high response rates, even for patients who have been given steroids to manage CRS, although prolonged systemic corticosteroid use has been shown to disrupt CAR persistence and efficacy. 248 Given the importance of Dex in glioma symptom management, successful CAR T cell trial design must identify allowable Dex concentrations. Most CAR T cell trials limit Dex levels to no more than 4-6 mg/d, and at this concentration, we have successfully manufactured clinically sufficient levels of CAR T cells from patients, have detected increased inflammatory cytokines post CAR T cell infusion, and in one patient CAR T cells elicited a complete response. 69 These findings provide initial evidence that low levels of Dex may be able to be used to manage tumor and/or immune inflammatory reactions without significant deleterious effects on CAR T cell function, but more clinical experience is required to fully delineate the impact on therapeutic activity and patient outcomes.
Bevacizumab (Avastin) is FDA-approved for the treatment of recurrent GBM, and acts as a ligand-sink against the vascular endothelial growth factor receptor (VEGF). Disrupting VEGF/VEGFR2 signaling inhibits angiogenesis, normalizes tumor vasculature and re-establishes the blood-brain barrier. The effects of bevacizumab on CAR T cell therapy are anticipated to be multifaceted. First, by normalizing the tumor vasculature, bevacizumab alters MR imaging features, resulting in decreased T1 contrast enhancement and FLAIR sequences. 253 These imaging changes confound disease assessment when using bevacizumab in conjunction with CAR T cells therapy and therefore necessitate using OS vs PFS for a response endpoint.
Second, bevacizumab can be an effective non-steroid anti-inflammatory for managing symptoms of cerebral edema, thereby providing an alternative to immunosuppressive corticosteroids such as dexamethasone. 254 Additionally, bevacizumab may augment CAR T cell therapy by inhibiting the immune suppressive effects of VEGF, as well as promote tumor lymphocyte trafficking. 255, 256 Preclinical models in neuroblastoma have demonstrated enhanced efficacy of combination bevacizumab and GD2-CAR-T cells. 257 Combination treatment resulted in high infiltration of GD2-CAR T cells which resulted in increased IFNγ production. Given bevacizumab's role in enhancing lymphocyte trafficking and blocking VEGF immunosuppressive effects, it may be a promising combination therapy with CARs for treatment of solid tumors. Whether there is enhanced clinical efficacy with combination CAR T cells and bevacizumab in GBM and other brain tumors still requires clinical validation.
| Clinical and molecular endpoints and correlative studies
Clinical and molecular endpoints and correlative studies col- cell expansion and persistence is also be an important molecular endpoint, as it has been associated with clinical response in CD19-CAR T for ALL. 45, 258 Additionally, persistence of CAR T cells of at least 1 month has been associated with overall response in patients with metastatic melanoma. 259 Other clinically important correlates include an assessment of the tumor and TME, which require biopsy. Indeed, tumor PD-L1 upregulation was found after EGFRvIII-CAR delivery. 80 PD-L1 upregulation is clinically meaningful in the context of future combination trials with CAR T cells and immune-checkpoint inhibitors. Well-designed correlative studies will provide answers as well as raise new questions, such as what is the optimum frequency of CSF biopsy and tumor biopsy to evaluate for treatment response.
| SUMMARY AND PER S PEC TIVE S
The success of immunotherapy is revolutionizing cancer therapy and improving outcomes for patients with a wide variety of cancers. While brain tumors are considered some of the most difficult to treat of solid tumors, progress in the immunotherapy is raising optimism for its potential to make inroads in their treatment. Evidence that adoptively transferred T cells, including CD19-CARs and melanoma-targeted TCR-engineered or TILs, can traffic to the brain and eliminate disease supports the notion that CAR T cells may eventually prove effective against other primary and metastatic brain tumors. Advances in the understanding of neuroimmunology alongside advances in cancer immunotherapy have provided a platform to create more effective treatments for brain tumors. CAR T cell therapy for brain tumors faces major obstacles, such CAR T cell persistence and trafficking to the CNS, adaptive immune resistance and other immunosuppressive elements of the TME, and tumor heterogeneity. CAR T cell clinical studies have provided valuable insights that will help in shaping future trials, and initial indications from these trials point to the need for combination therapies that can address several obstacles simultaneously or in sequence. It is critical to ensure that future trial designs not only inform on safety, but also provide information on mechanisms underlying response and resistance, as this information will provide the path forward to overcoming the formidable obstacles to treatment.
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